oxandrolone has been researched along with Depression in 3 studies
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
Excerpt | Relevance | Reference |
---|---|---|
"Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions." | 5.62 | Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α. ( Abed, AF; Alfaraj, M; Hall, FS; Hammad, AM; Ibrahim, YA; Jarrar, Y; Khdair, SI, 2021) |
"Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions." | 1.62 | Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α. ( Abed, AF; Alfaraj, M; Hall, FS; Hammad, AM; Ibrahim, YA; Jarrar, Y; Khdair, SI, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Hammad, AM | 1 |
Ibrahim, YA | 1 |
Khdair, SI | 1 |
Hall, FS | 1 |
Alfaraj, M | 1 |
Jarrar, Y | 1 |
Abed, AF | 1 |
Freriks, K | 1 |
Verhaak, CM | 1 |
Sas, TC | 1 |
Menke, LA | 1 |
Wit, JM | 1 |
Otten, BJ | 1 |
de Muinck Keizer-Schrama, SM | 1 |
Smeets, DF | 1 |
Netea-Maier, RT | 1 |
Hermus, AR | 1 |
Kessels, RP | 1 |
Timmers, HJ | 1 |
Ross, JL | 1 |
Kushner, H | 1 |
Kowal, K | 1 |
Bardsley, M | 1 |
Davis, S | 1 |
Reiss, AL | 1 |
Tartaglia, N | 1 |
Roeltgen, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome[NCT00348946] | Phase 2 | 93 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Outcome measures were tested using The Piers-Harris Self Concept Scale. Scoring provides a total standard score and scores on six subscales: physical appearance and attributes, freedom from anxiety, intellectual and school status, behavioral adjustment, happiness and satisfaction, and popularity. Subscales are summed and standardized to provide the total standard score with a mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scores imply better function. (NCT00348946)
Timeframe: 2 years per subject
Intervention | units on a scale (Mean) |
---|---|
Oxandrolone | 105 |
Placebo | 100 |
Outcome measures were tested using the Differential Ability Scales - 2nd edition (DAS-II). DAS-II provides an age- and sex-standardized assessment of intellectual functioning (General Concept Ability subscale similar to IQ) in children ages 2-17 years of age (mean=100, SD=15). The Verbal Cluster measures the child's ability to define words and perform verbal reasoning tasks. The Nonverbal Cluster measures the child's inductive and sequential reasoning abilities. The Spatial Cluster measures visuospatial construction ability, spatial memory, and spatial reasoning. Data is expressed as standard scores with mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scores imply better function. (NCT00348946)
Timeframe: 2 years per subject
Intervention | score on a scale (Mean) | |||
---|---|---|---|---|
DAS: General Concept Ability | DAS: Verbal Cluster | DAS: Nonverbal Cluster | DAS: Spatial Cluster | |
Oxandrolone | 96 | 92 | 102 | 96 |
Placebo | 94 | 90 | 101 | 94 |
Outcome measures were tested using the following assessments: Bruininks-Osertesky Test of Motor Proficiency (BOT) subscales of (1) Visual Motor Control, (2) Upper limb Speed, and (3) Strength, Physical and Neurological Evaluation for Soft Signs (PANESS), and Hand Strength Dynamometer. BOT assess the child's motor development and includes standard scores (mean=100, SD=15) and subtest scores and is normed for sex and age (4-14.5 years). PANESS assesses the time required to press thumb to 4 fingers 20 times for the dominant and nondominant hands and includes standard scores (mean=100, SD=15) with age-specific norms (4-18 years). Hand strength dynamometer assess hand strength in the dominant and nondominant hands and includes standard scores (mean=100, SD=15). Data is expressed as standard scores with mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scorers imply better function. (NCT00348946)
Timeframe: 2 years per subject
Intervention | score on a scale (Mean) | ||||
---|---|---|---|---|---|
BOT Visual-motor control SS | BOT Upper limb speed SS | BOT Strength SS | Hand Dynamometer SS- dominant hand | PANESS SS- dominant hand | |
Oxandrolone | 86 | 92 | 88 | 123 | 91 |
Placebo | 81 | 89 | 85 | 118 | 91 |
Outcome measures were tested using the following social assessments: The Child Behavior Checklist (CBCL) and The Children's Depression Inventory (CDI). The CBCL is standardized measure of behavior problems and social competency normed for children ages 4-16. Higher scores indicate more problems, with the cutoff for the clinical range at a t score greater than or equal to 67. The CDI assess cognitive, affective and behavioral signs of depression in children ages 6-17. The CDI total score reflects the presence of overall depressive symptoms. All scores are expressed as t-scores with a mean of 50 and SD of 10. Lower scores imply better function and higher scores indicate more problem behaviors. (NCT00348946)
Timeframe: 2 years per participants
Intervention | score on a scale (Mean) | |||
---|---|---|---|---|
CBCL: behavior total t-score | CBCL: internalizing total t-score | CBCL: externalizing total t-score | CDI: total t-score | |
Oxandrolone | 56 | 54 | 51 | 45 |
Placebo | 59 | 57 | 54 | 47 |
Outcome measures were tested using the following cognitive assessments: Digit Span Backward, A Neuropsychological Assessment (NEPSY) subscales of (1) Phonemic Fluency and (2) Semantic Fluency, and Connors' Continuous Performance Test (CPT-II) subscales (1) Omissions, (2) Commissions, (3) Hit Reaction, (4) Variability, and (5) Preservations. Digit Span Backward tests working memory and is normed for children ages 5-16 years. Phonemic Fluency measures the number of words that the child can name beginning with the letters F and S (ages 6-12). Semantic Fluency measures the number of words the child can name in the categories food and drink (ages 4-12). CPT-II measures the ability to maintain attention over an extended period of time. All scores are reported as standard scores with a mean of 100 and SD of 15. The minimum standard score is 50; the maximum standard score is 145. Higher scores imply better function. (NCT00348946)
Timeframe: 2 years per participant
Intervention | score on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Digit span backward | Phonemic fluency | Semantic fluency | CPT: omissions | CPT: commissions | CPT: hit reaction time | CPT variability | CPT: preservations | |
Oxandrolone | 96 | 95 | 99 | 88 | 101 | 84 | 86 | 76 |
Placebo | 92 | 91 | 94 | 83 | 100 | 80 | 86 | 74 |
2 trials available for oxandrolone and Depression
Article | Year |
---|---|
Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life and social-emotional functioning in young adults with Turner syndrome.
Topics: Adolescent; Adult; Androgens; Cognition; Depression; Emotional Intelligence; Emotions; Estrogens; Fe | 2015 |
Androgen Treatment Effects on Motor Function, Cognition, and Behavior in Boys with Klinefelter Syndrome.
Topics: Androgens; Anxiety; Child; Child Behavior; Child, Preschool; Cognition; Depression; Double-Blind Met | 2017 |
1 other study available for oxandrolone and Depression
Article | Year |
---|---|
Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α.
Topics: Anabolic Agents; Animals; Anti-Inflammatory Agents; Behavior, Animal; Cytokines; Depression; Disease | 2021 |